Kymera Investor Day Presentation Deck

NEW Expanded E3 Ligase Toolbox Understanding Degradation (PK/PD) Across Tissue Types Proprietary Chemistry Center for Molecular Glue Discovery KYMERA Proprietary PegasusTM TPD Platform Key Capabilities E3 ligase Whole-Body Atlas: Identification of the expression profiles of ~600 unique E3 ligases Match target protein with appropriate E3 ligase based on expression, distribution, intracellular localization, and biology through a machine learning based algorithm Toolbox of proprietary ligands leverages the E3 Ligase Whole-Body Atlas Quantitative System Pharmacology Model measures and predicts diverse sets of parameters that impact protein levels Based on understanding of PK/PD, both in vitro and in vivo, and across different tissues and cell types Comprehensive hit finding technologies toolbox Proprietary chemistry expertise enables the design and optimization of both E3 ligases and target protein binders, Al enabled optimization Ability to convert into degraders with optimal pharmaceutical properties Identification of novel E3 ligases, beyond CRBN, that enable degradation of high value "undrugged and un-ligandable" proteins through small molecule interactions Established collaborations with A-Alpha Bio and two academic organizations in the US to enable this novel and differentiated approach to molecular glues discovery UD Undrugged Targets ID Inadequately Drugged Targets with Clear Degrader Advantage ©2021 KYMERA THERAPEUTICS, INC. TR Clinically Validated Targets Enabled by E3 Ligase Tissue Restricted Expression KYMERA R&D DAY - December 16th, 2021 DISCOVERY IMPACT BY TARGET TYPE ID UD ID UD ID UD UD TR TR TR PAGE 88

View entire presentation